Free Trial

Solventum Co. (NYSE:SOLV) Shares Bought by Vanguard Group Inc.

Solventum logo with Medical background
Remove Ads

Vanguard Group Inc. boosted its holdings in shares of Solventum Co. (NYSE:SOLV - Free Report) by 0.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,266,893 shares of the company's stock after acquiring an additional 75,631 shares during the quarter. Vanguard Group Inc. owned about 9.42% of Solventum worth $1,074,591,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. State Street Corp raised its holdings in Solventum by 3.1% in the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company's stock valued at $425,818,000 after buying an additional 185,938 shares during the period. Geode Capital Management LLC increased its position in shares of Solventum by 4.0% during the third quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company's stock valued at $232,608,000 after acquiring an additional 128,317 shares during the last quarter. Hotchkis & Wiley Capital Management LLC purchased a new stake in shares of Solventum in the 3rd quarter valued at approximately $125,488,000. Boston Partners acquired a new position in shares of Solventum in the 4th quarter worth approximately $110,378,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Solventum by 0.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,053,771 shares of the company's stock worth $73,469,000 after purchasing an additional 3,745 shares during the period.

Solventum Stock Up 1.3 %

Shares of Solventum stock traded up $0.96 on Wednesday, reaching $77.30. 360,857 shares of the company were exchanged, compared to its average volume of 1,420,624. The stock's 50 day moving average price is $75.60 and its 200-day moving average price is $71.97. The company has a market cap of $13.37 billion and a P/E ratio of 28.06. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $85.92. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Remove Ads

Analyst Ratings Changes

A number of research firms have commented on SOLV. Mizuho upped their price target on Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a research note on Monday, March 3rd. Piper Sandler increased their target price on Solventum from $75.00 to $84.00 and gave the stock a "neutral" rating in a research note on Friday, February 28th. Wells Fargo & Company raised their target price on Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a report on Friday, February 28th. Bank of America boosted their price target on shares of Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group raised their price objective on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, Solventum currently has an average rating of "Hold" and a consensus target price of $79.86.

Check Out Our Latest Report on SOLV

Solventum Company Profile

(Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Recommended Stories

Institutional Ownership by Quarter for Solventum (NYSE:SOLV)

Should You Invest $1,000 in Solventum Right Now?

Before you consider Solventum, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.

While Solventum currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Trump Tariffs Tumble the Stock Market—Here’s How to Protect Your Money
Donald Trump Owns These 7 Stocks, Should You?
 5 Stocks to BUY NOW in April 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads